Children's Mercy Kansas City

SHARE @ Children's Mercy
Manuscripts, Articles, Book Chapters and Other Papers
4-23-2019

Direct Lung Sampling Indicates That Established Pathogens
Dominate Early Infections in Children with Cystic Fibrosis.
Peter Jorth
Zarmina Ehsan MD
Children's Mercy Hospital

Amir Rezayat
Ellen Caldwell
Christopher Pope

See next page for additional authors

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/papers
Part of the Pediatrics Commons, Pulmonology Commons, and the Respiratory Tract Diseases
Commons

Recommended Citation
Jorth P, Ehsan Z, Rezayat A, et al. Direct Lung Sampling Indicates That Established Pathogens Dominate
Early Infections in Children with Cystic Fibrosis. Cell Rep. 2019;27(4):1190-1204.e3. doi:10.1016/
j.celrep.2019.03.086

This Article is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for
inclusion in Manuscripts, Articles, Book Chapters and Other Papers by an authorized administrator of SHARE @
Children's Mercy. For more information, please contact library@cmh.edu.

Creator(s)
Peter Jorth, Zarmina Ehsan MD, Amir Rezayat, Ellen Caldwell, Christopher Pope, John J. Brewington,
Christopher H. Goss, Dan Benscoter, John P. Clancy, and Pradeep K. Singh

This article is available at SHARE @ Children's Mercy: https://scholarlyexchange.childrensmercy.org/papers/1652

Article

Direct Lung Sampling Indicates That Established
Pathogens Dominate Early Infections in Children
with Cystic Fibrosis
Graphical Abstract

Authors
Peter Jorth, Zarmina Ehsan,
Amir Rezayat, ..., Dan Benscoter,
John P. Clancy, Pradeep K. Singh

Correspondence
john.clancy@cchmc.org (J.P.C.),
singhpr@uw.edu (P.K.S.)

In Brief

Highlights
d

BALs from CF children with mild disease primarily contain
established CF pathogens

d

Microbiota in BALs lacking CF pathogens were
indistinguishable from controls

d

Rare oral organisms were found in some BALs containing
abundant CF pathogens

d

CF pathogens strongly correlated with inflammation and oral
organisms did not

Jorth et al., 2019, Cell Reports 27, 1190–1204
April 23, 2019 ª 2019
https://doi.org/10.1016/j.celrep.2019.03.086

Jorth et al. studied lung lavages from CF
children using sequence-based methods
and extensive controls for upper airway
and reagent contamination. The results
argue against the CF infection
pathogenesis hypothesis postulating that
diverse communities of mostly oral
bacteria inhabit lungs early in disease and
suggest that differences in the samples’
microbial diversity were driven by
changes in the abundance of
conventional CF pathogens against a
fairly constant background of
contaminants.
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SUMMARY

Culture and sequencing have produced divergent
hypotheses about cystic fibrosis (CF) lung infections.
Culturing suggests that CF lungs are uninfected
before colonization by a limited group of CF pathogens. Sequencing suggests diverse communities of
mostly oral bacteria inhabit lungs early on and diversity decreases as disease progresses. We studied
the lung microbiota of CF children using bronchoscopy and sequencing, with measures to reduce
contamination. We found no evidence for oral bacterial communities in lung lavages that lacked CF pathogens. Lavage microbial diversity varied widely, but
decreases in diversity appeared to be driven by
increased CF pathogen abundance, which reduced
the signal from contaminants. Streptococcus, Prevotella, and Veillonella DNA was detected in some lavages containing CF pathogens, but DNA from these
organisms was vastly exceeded by CF pathogen
DNA and was not associated with inflammation.
These findings support the hypothesis that established CF pathogens are primarily responsible for
CF lung infections.

INTRODUCTION
People with cystic fibrosis (CF) suffer from chronic bacterial lung
infections that culminate in respiratory failure (Burns et al., 2001;
Emerson et al., 2002; Lyczak et al., 2002). Despite intensive
research, key questions about CF infection pathogenesis remain
obscure. One fundamental question is which bacterial species
are present in the lungs of people with CF and which cause dis-

ease. Addressing this question is critical to devising effective disease prevention and treatment approaches.
Decades of study using culture-based methods suggest that
the lungs of people with CF are uninfected at birth and that
over time transient and then permanent infections develop
(Burns et al., 2001). Importantly, a restricted group of organisms
(called ‘‘CF pathogens’’ below) have been thought responsible
for infection. The list of CF pathogens include Haemophilus
influenzae, Staphylococcus aureus, Pseudomonas aeruginosa,
Burkholderia spp., and a few others (Gibson et al., 2003; Lyczak
et al., 2002); epidemiological and clinical observations associate
these organisms with disease (Emerson et al., 2002; Gibson
et al., 2003).
Recent work using DNA sequencing to identify bacteria in CF
airways has produced several new ideas that have challenged
this established model. First, DNA-based methods suggest
that diverse communities of bacteria that were not previously
thought to cause CF infections (a group we call ‘‘non-conventional organisms’’ below) dominate lungs before CF pathogens
appear, when lung function is generally preserved (Brown
et al., 2014; Coburn et al., 2015; Frayman et al., 2017; Madan
et al., 2012; Muhlebach et al., 2018; Pittman et al., 2017). This
finding raises the possibility that non-conventional organisms
could protect lungs from pathogen infection. Alternatively,
these organisms could produce initial lung injury that promotes
pathogen colonization.
Second, although studies using DNA-based methods generally find that CF pathogens dominate lung microbiota in
advanced disease (Coburn et al., 2015; Goddard et al., 2012;
Zhao et al., 2012), sequence-based analyses indicate that
diverse communities of non-conventional organisms co-exist
with CF pathogens after CF pathogens become dominant (Coburn et al., 2015; Zhao et al., 2012). This finding raises the possibility that non-conventional organisms could either enhance
or dampen pathogen-induced injury or treatment responses,or
independently contribute to disease.
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Finally, DNA-based analyses suggest that the diversity of
lung microbiota may be a key disease parameter. Many
studies have found that the relative abundance of non-conventional organisms and the diversity of lung microbiota in airway
samples decrease as age and disease severity advances
(Coburn et al., 2015; Cox et al., 2010; Fodor et al., 2012;
Klepac-Ceraj et al., 2010; Stokell et al., 2015; Zhao et al.,
2012). This finding raises the possibility that declining diversity
could contribute to lung disease and strategies that maintain
diversity could be beneficial.
Reconciling the new ideas suggested by DNA-based methods
with the established pathogenesis model is challenging, as both
culture- and DNA-based approaches have significant and in
some ways opposing limitations. Culture analysis is based on
the premise that infection is generally caused by a single or small
number of pathogens that can be isolated in pure culture (Baron
et al., 2013; Burns and Rolain, 2014). Thus, clinical laboratories
selectively culture samples and filter results to remove organisms not considered pathogenic (Tunney et al., 2008), which
are viewed as contaminants (Baron et al., 2013; Mahboubi
et al., 2016). This could be problematic, as culture-based analysis could fail to identify non-conventional organisms.
In contrast, DNA-based methods cast a wider net, identifying
culturable and unculturable organisms and DNA from live and
dead cells without filtering for contaminants (Kennedy et al.,
2014; Salter et al., 2014; Weiss et al., 2014). This could be
problematic because many of the non-conventional organisms
detected by sequencing are highly abundant in oropharyngeal
secretions that contaminate airway samples (Bik et al., 2010;
Coburn et al., 2015; Cox et al., 2010; Dewhirst et al., 2010; Fodor
et al., 2012; Goddard et al., 2012; Klepac-Ceraj et al., 2010; Lim
et al., 2013; Price et al., 2013; Twomey et al., 2013; Zemanick
et al., 2015; Zhao et al., 2012). Contamination is particularly
problematic for throat and sputum samples and when lung bacterial biomass is low (e.g., early in disease), as contaminants will
have more consequential effects on measurements (Coburn
et al., 2015; Salter et al., 2014). DNA-based methods could
also detect bacteria that are inhaled or aspirated but killed by
host defenses before they replicate. Thus, DNA-based methods
will detect contaminants and dead organisms that do not
actively grow in the lung.
Here, we sought to investigate the composition of lung microbiota in CF children by combining the high sensitivity of
sequence-based approaches and directed bronchoscopic sampling, with measures to reduce exposure to oropharyngeal secretions and extensive controls to help identify contaminants.
We focused on CF children, as the results of culture- and
DNA-based methods differ most in early lung disease and understanding early infection is critical to intervention strategies to
preserve lung function.
RESULTS
Subjects
We studied 22 children and young adults (mean, 13.1 years old;
range, 6–21 years old) all with mild CF lung disease (mean forced
expiratory volume [FEV1], 92% ± 15% predicted) who underwent
bronchoscopy for clinical indications. None of the subjects were

taking cystic fibrosis transmembrane conductance regulator
(CFTR) modulators. Table S1 provides additional information
about study subjects.
Sampling Approach and Controls
Reducing and controlling for contamination are particularly critical when using DNA-based methods due to their sensitivity
and because results are not filtered by clinical laboratories that
disregard and remove organisms considered to be contaminants. Bronchoalveolar lavage (BAL) samples may become
contaminated with bacterial DNA from the oropharyngeal
compartment, secretions aspirated into the lung during the procedure, and non-patient sources, including the bronchoscope
and reagents (Culver et al., 2003; Kennedy et al., 2014; Kirschke
et al., 2003; Mehta and Minai, 1999; Salter et al., 2014; Srinivasan
et al., 2003; Weiss et al., 2014).
We eliminated scope contact with oropharyngeal mucosa
and likely reduced procedure-associated aspiration by performing bronchoscopy through cuffed endotracheal tubes
placed during a separate laryngoscopy procedure (Figure 1A);
however, some upper airway secretions likely entered the
endotracheal tube during placement. We also collected mouth
rinses and throat aspirates by using a sterile suction catheter
immediately before bronchoscopy from each subject for comparison (Figure 1B).
Using these methods, we performed BAL of 4 lobar bronchi
in each subject (with the scope in the wedged position, see
STAR Methods), beginning with the right middle lobe from
which 2 saline lavages were separately collected (BAL-1a and
b). Lavage was subsequently performed in an adjacent
segmental bronchus in the right upper lobe (BAL-2), then the
left lower lobe (BAL-3), and finally in the lung segment that appeared most diseased during bronchoscopy or on prior imaging (BAL-4) (Figure 1A).
DNA contamination contributed by reagents and the suction
channels of bronchoscopes and catheters (which were used for
throat aspirates) are difficult to reduce. Thus, we measured bacterial DNA in saline washes (saline from same source that was
used for BALs) from each bronchoscope and catheter, immediately before bronchoscopies and throat aspirates were performed
(called ‘‘scope or catheter pre-washes’’ or collectively called ‘‘instrument controls,’’ below) as background measurements of
contamination from non-patient sources (Figure 1B).
Measuring Background Contamination in BALs
Scope pre-washes consistently contained 102 bacterial
genome copies/mL (Figures S1A and S1B; Table S2) (mean,
293; range, 43–651), similar to instrument and reagent controls
in other studies (Table S3). Sequencing revealed a diverse
collection of microbial DNA in scope pre-washes, including CF
pathogens (see Figure 1C for genera considered CF pathogens)
(Figure S1C; Tables S4 for taxa and S5 for sequencing read
counts and Good’s coverage for each sample). The fact that
DNA-based analysis of instrument control samples identified
CF pathogens (see below) prior to contact with subjects highlights one challenge in interpreting sequencing results.
Two findings indicated that most bacterial DNA in scope
washes originated from processing reagents, rather than the
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Figure 1. Study Design and Bacterial Burdens in Samples
(A) Endotracheal tubes eliminated bronchoscope contact with oropharyngeal (OP) tissues.
(B) Control samples included mouth rinses, throat aspirates, saline passed through each sterile catheter (used for throat aspirates) and bronchoscope prior to use
(called scope and catheter pre-washes), and reagent controls.
(C) Organisms considered CF pathogens in this study.
(D) Total bacterial abundance detected in mouth rinse, catheter pre-wash, throat aspirate, scope pre-wash samples (n = 22 for each), and BALs (n = 102 as 4
BAL samples were obtained for most subjects). Line indicates mean, and error bars standard deviation values. Here and below, qPCR data are the mean of 2
technical replicates.
See also Figures S1 and S2 and Tables S1, S2, and S3.

scope channel. Bacterial DNA abundances in scope and catheter pre-washes and in saline used for controls (and subsequent
BALs) that was not passed through any device were similar (Figure S1A). In addition, the microbiota profiles of scope and catheter pre-washes exhibited different patterns depending on the
reagent batches used for processing sequencing libraries
(Figure S1C).
We tested the hypothesis that scope pre-washes would represent the contaminating DNA in subsequently obtained BALs by
serially passing 10-mL saline aliquots through 3 bronchoscopes
used in this study and found bacterial DNA abundance essentially unchanged in serial samples (Figure S1B). This finding indicates that the background DNA signal (likely derived from re-
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agents, see Figure S1C) would also likely be detectable in
BALs. We accounted for this contamination in the analyses of
BALs described below.
BALs from CF Children Vary Widely in Bacterial DNA
Abundance
We measured the total bacterial burden in all mouth, throat, BAL,
and control samples. BAL bacterial DNA concentrations ranged
from 102 genome copies/mL (levels seen in scope pre-wash
controls) to >106 genome copies/mL, which was higher than any
other sample type (Figure 1D; Table S2). Notably, the bacterial
concentration in serial BAL samples taken from the same subject
sometimes differed by an order of magnitude (Figure S2; Table

S2), and BAL-4 (obtained from the lung segment that appeared
most diseased) generally contained the most bacterial DNA.
BAL Samples with More Bacteria Are Less Diverse
DNA-based analyses suggest that microbial diversity may be a
key disease-associated parameter, so we measured the Shannon diversity index in BALs and tried to understand differences
in diversity among the samples. We focused first on the initially
obtained BAL-1a samples, as they are unaffected by DNA
carry-over from other lung sites. Thus, the difference between
the bacterial DNA content in each paired scope pre-wash and
the corresponding BAL-1a will reflect bacterial DNA recovered
from the targeted lung segment. We plotted the Shannon index
of each BAL-1a as a function of the DNA content difference between each BAL-1a and its paired scope pre-wash and found a
strong inverse relationship; as bacterial DNA recovery from the
lung increased, Shannon diversity decreased (Figure 2A; Pearson r = 0.87, p < 0.0001).
We extended this analysis to include BALs from all sites (i.e.,
BALs 1–4), in this case examining Shannon diversity as a function
of total bacterial DNA concentration, and again found a strong
negative relationship (Figure 2B; Pearson r = 0.80, p < 0.001).
Notably, the negative association between Shannon diversity
and bacterial DNA abundance was absent for oral and throat
samples (Figure 2C; Pearson r = 0.30, p = 0.18; and Figure S3;
Pearson r = 0.05, p = 0.81), which are sites known to harbor
diverse resident microbiota (Dewhirst et al., 2010).
Increases in Pathogen Abundance Drive Diversity
Declines
We investigated the contributions of CF pathogens (defined in
Figure 1C) and non-conventional organisms to the Shannon diversity index variation of BALs by using both taxa absolute and
relative abundance measurements. Absolute abundance of individual taxa was calculated by multiplying total bacterial abundance by taxa relative abundance (see experiments validating
this approach in Figure S4). As shown in Figure 2D, reduced
BAL Shannon diversity was associated with marked increases
in the absolute abundance of CF pathogens (r = 0.87, p <
0.001, Pearson correlation). In contrast, the absolute abundance
of non-conventional organisms was relatively constant over
the wide range of BAL Shannon diversity observed (Figure 2E;
r = 0.21, p = 0.03, Pearson correlation).
The dominant effect of CF pathogen absolute abundance in
driving reduced diversity was also apparent by comparing the
BALs with the highest and lowest extremes of Shannon diversity.
As shown in Figure 2F, the lowest diversity BALs contained a
much higher absolute abundance of CF pathogens than the
highest diversity BALs, but the absolute abundance of non-conventional organisms did not significantly differ between the
groups (Figure 2F).
These data suggest that the low diversity of BALs with high
bacterial burdens is driven by increases in the absolute abundance of CF pathogens against a relatively static background of
non-conventional organisms. Notably, plotting the data in terms
of relative abundance (Figures 2G and 2H) completely obscured
the differential contribution of CF pathogens and non-conventional organisms to BAL Shannon diversity (see Discussion).

The Non-conventional Organisms in BALs Are Similar to
Instrument Pre-wash Controls
We focused further analysis on the non-conventional organisms
in BALs because the identity and origins of these organisms are a
key area of controversy in CF (O’Toole, 2018). Previous work
suggests that many non-conventional organisms in CF airway
samples are oral organisms (Bik et al., 2010; Coburn et al.,
2015; Cox et al., 2010; Dewhirst et al., 2010; Fodor et al.,
2012; Goddard et al., 2012; Klepac-Ceraj et al., 2010; Lim
et al., 2013; Price et al., 2013; Twomey et al., 2013; Zemanick
et al., 2015; Zhao et al., 2012). Some studies suggest that
these organisms inhabit CF lungs, whereas other studies raise
the possibility that they are contaminants introduced from
oropharyngeal secretions. However, relatively few studies have
used bronchoscopy sampling performed through endotracheal
tubes placed during a separate laryngoscopy procedure as
done here, and we hoped that this approach would limit oropharyngeal contamination (see above).
We began by ordering the BALs by their total bacterial DNA
abundance (Figure 3A) and found that non-conventional organisms generally dominated BALs with low bacterial abundance,
whereas CF pathogens dominated BALs with high abundance
(Figure 3B). We then examined the similarity of each BAL to subject-paired mouth and throat samples using the Morisita-Horn
dissimilarity index (Wolda, 1981).
As expected, the high biomass BALs that were dominated by
CF pathogens (Figure 3B, right side of graph) were very dissimilar
to their paired mouth and throat samples (Figures 3C, 3D, and 4).
This finding is consistent with data indicating that CF pathogens
are not abundant in the mouth and throat (Figure S5; Table S4).
Surprisingly, the low bacterial biomass BALs that were dominated by non-conventional organisms (Figures 3B, left side of
graph) were also very dissimilar to subject-paired mouth and
throat samples (Figures 3C, 3D, and S5; Table S4).
The dissimilarity of low bacterial biomass BALs to mouth and
throat samples led us to hypothesize that contaminants contributed by reagents and instruments may account for the non-conventional organism DNA in these samples. We tested this hypothesis in three ways. First, we compared BALs to their
paired scope pre-wash controls and found the BALs with low
bacterial DNA abundance to be more similar to subject-paired
scope pre-washes than to paired mouth and throat samples
(compare Figures 3E to 3C and 3D).
Second, we plotted the relative abundance of taxa in BALs as
a function of their abundance in instrument controls. Taxa that
were instrument or reagent contaminants would likely show a
linear abundance relationship in these two sample types,
whereas taxa originating from subjects’ lungs should be more
abundant in BALs relative to instrument controls. As shown in
Figure 3F, the relative abundance of non-conventional taxa
(black points) in instrument controls and BALs exhibited a strong
linear relationship. In contrast, CF pathogens (colored points)
were more abundant in BALs than in instrument controls.
Third, we computationally removed CF pathogens from the
results to increase the resolution of the non-conventional organisms present and compared BALs to mouth, throat, and
control samples. Regardless of total bacterial DNA content,
the taxonomic profiles of non-conventional organisms in
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Figure 2. Changes in the Absolute Abundance of CF Pathogens Drive BAL Shannon Diversity Differences
(A) Relationship between the Shannon diversity index and bacterial DNA recovered from the first BAL obtained from each subject (BAL-1a). Bacterial DNA recovery was measured by subtracting bacterial DNA levels in patient-paired scope pre-washes from the values in subsequent BAL-1a sample; n = 17 as samples
from 5 subjects (i.e., 5, 6, 8, 17, and 18) were not included because BAL samples contained lower bacterial concentrations than paired scope pre-washes.
(B and C) Relationship between BAL Shannon diversity and total bacterial DNA levels in all 102 BALs (B) and 22 mouth rinses (C) collected (see Figure S3 for data
from throat samples). Linear regression lines with 95% confidence intervals and Pearson correlation coefficients with p values are shown in (A)–(C).
(D and E) Relationship between the absolute abundance of CF pathogens (D) and non-conventional organisms (E) and Shannon diversity indices of BALs (n =
102). Linear regression lines and Pearson correlation coefficients with respective p values are shown.
(F) Absolute abundance of CF pathogens and non-conventional organisms in the 25 BALs with the lowest (left) and highest (right) Shannon diversity indices (mean
values for each group are indicated in black bars). Error bars indicate SD values; *p < 0.005, unpaired two-tailed t test.
(G and H) Data from the 102 BALs presented in (D) and (E), but plotted in terms of relative rather than absolute abundance of CF pathogens (G) and non-conventional organisms (H). The relative abundance plots obscure the finding that CF pathogen abundance drives the Shannon diversity differences. Graphs include
linear regression and Pearson correlation coefficients with respective p values. Here and below taxa abundance data obtained from sequencing are the mean of 3
technical replicates.
Also see Figures S3 and S4, Table S4 for taxa abundance data, and Table S5.
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BALs were more similar to catheter and scope pre-wash controls than to mouth or throat samples (Figure 4A). MorisitaHorn dissimilarity and principal coordinates analyses corroborated these findings (Figures 4B and 4C). Furthermore, principal coordinates analyses showed that non-conventional organisms in BALs grouped with instrument control samples
that were processed using the same reagent batches (Figure 4C). These findings are consistent with the strong reagent-batch effect on the microbiota identified in saline and
instrument controls (Figure S1). Taken together, these findings
suggest that most of non-conventional organisms in the BALs
we studied were dissimilar to patient-paired oral samples and
were likely contaminants contributed by processing reagents.
BALs Lacking CF Pathogens Did Not Contain Microbiota
Distinguishable from Background
Although the similarity and clustering analyses above suggest
that reagent contaminants contribute significantly to the nonconventional organisms in the BALs we collected, the findings do not rule out the possibility that some non-conventional organisms originate from the lungs. We used two approaches to examine this possibility further, focusing first
on BALs that contained very low abundances of CF pathogens (less than 150% of the maximum pathogen DNA levels
found in paired scope pre-washes, i.e., <164 CF pathogen
genome copies/mL).
First, we plotted the relative abundance of non-conventional
taxa found in these BALs as a function of their abundance in
instrument controls. As noted above, taxa that originated
from the subjects’ lungs would be expected to be more abundant in BALs. As shown in Figure 3G, the abundance of nonconventional taxa in BALs and instrument controls exhibited a
strong linear relationship, with values falling along the identity
line.
We also used a statistical test (the negative binomial test
[Love et al., 2014]) to identify non-conventional organisms
over-represented in BALs, relative to paired instrument and reagent controls and found no taxa that were overrepresented in
low pathogen abundance BALs as compared to scope prewash samples (Table 1) (see Table S6 for proof-of-principle control analyses). Thus, these analyses found no evidence for an
identifiable microbiota that was distinct from instrument controls
in BALs containing a low abundance of CF pathogens.

Some Pathogen-Infected BALs Contained DNA from
Oral Bacteria
We used the statistical analysis described above to determine if
any non-conventional organisms were overrepresented in BALs
that did contain CF pathogens (i.e., BALs with >164 CF pathogen
genome copies per mL, which is >150% of the maximum value in
instrument and reagent controls). In contrast to the results from
low pathogen abundance BALs, we found three non-conventional genera, Streptococcus, Prevotella, and Veillonella, overrepresented in BAL samples relative to controls (Table 1). In
addition, an uncultured organism belonging to the Alcaligenaceae family was overrepresented. Alcaligenaceae includes Achromobacter, Burkholderia, and Bordetella, so reads assigned to
Alcaligenaceae may have come from one of these CF pathogens. These findings suggest that Streptococcus, Prevotella,
and Veillonella genera may be present at a low abundance in
BALs that already contained CF pathogens.
Streptococcus, Prevotella, and Veillonella Are Vastly
Outnumbered by Pathogens
Examination of the profiles of non-conventional organisms (with
pathogens removed) (Figure 4A) suggested that Streptococcus,
Prevotella, and Veillonella were more abundant in BALs that
contained more bacterial DNA. To examine this further, we
plotted the absolute abundance of Streptococcus, Prevotella,
and Veillonella as a function of the total BAL bacterial DNA concentration (Figure 5A) and CF pathogen abundance (Figure 5B)
and found a strong positive relationship. With the exception of
6 (out of 102) BALs that contained trace levels of Streptococcus
DNA (10 genome copies/mL), Streptococcus, Prevotella, and
Veillonella were absent in BALs containing <1,000 bacterial
genome copies/mL (Figure 5A) or <100 CF pathogen genome
copies/mL (Figure 5B).
We examined the ratio of Streptococcus, Prevotella, and
Veillonella to CF pathogens in BALs and found CF pathogens in
far excess abundance. On average, there was 725-fold more pathogen DNA than Streptococcus, 2,334-fold more pathogen DNA
than Prevotella, and 6,476-fold more pathogen DNA than Veillonella (Figure 5C). Thus, these three non-conventional organisms
were almost always found in BALs that already contained abundant pathogens (Figure 5B) and, when present, were far outnumbered by CF pathogens (Figure 5C). These findings are consistent
with supplemental data presented by Hogan et al. (2016) (see their

Figure 3. Microbiota of BALs with Low CF Pathogen Abundance Are More Similar to Paired Scope Washes Than to Paired Mouth and Throat
Samples
(A) Total bacterial abundance in BAL samples, ordered from lowest to highest. Reference lines indicate mean and maximum scope pre-wash bacterial DNA loads.
Ordering of BAL samples (n = 102) is maintained in A–E.
(B) Relative abundance of CF pathogens (red bars) and non-conventional organisms (gray bars) in BAL samples.
(C–E) Morisita-Horn dissimilarity indices of BALs as compared to subject-paired mouth (C), throat (D), and instrument control (E) samples; 0 is maximum similarity,
1 is maximum dissimilarity. Dissimilarities were calculated using all identified bacterial operational taxonomic units (OTUs).
(F) Mean relative abundance of taxa in all 102 BALs plotted as a function of their mean relative abundance in instrument controls. CF pathogen taxa (colored
points) are labeled. The black line indicates the linear regression fit to non-conventional organism taxa (black points).
(G) Mean relative abundance of all non-conventional taxa in 34 BALs with low CF pathogen abundance (<164 CF pathogen genome copies/mL) plotted as a
function of their mean relative abundance in instrument controls. CF pathogens were computationally removed for this analysis. The black line indicates the linear
regression fit to the non-conventional organism OTUs.
In (F) and (G), Pearson correlations are indicated for each fit (r and p values).
See also Figure S5.
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Figure 4. Non-conventional Organisms in BALs Are Similar to Scope and Catheter Pre-washes but Different from Paired Mouth and Throat
Samples
(A) Relative abundance of non-conventional taxa detected in all 102 BALs (top); and 22 catheter and scope pre-washes, mouth and throat samples (bottom) after
CF pathogens were computationally removed.
(B) Morisita-Horn dissimilarity of non-conventional organisms in all 102 BALs (after pathogens were removed) as compared to non-conventional organisms in
subject-paired scope pre-wash, mouth rinse, and throat aspirate samples. Mean and SEM are indicated.
(C) Principal coordinates analysis of Morisita-Horn dissimilarities of non-conventional organisms (after pathogens removed) in BAL, mouth rinse, throat aspirate,
and instrument control samples described in (A). The scope and catheter pre-wash control samples separate into two groups along principle coordinate 1
according to the batch in which they were sequenced.
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Table 1. Non-conventional Taxa Significantly Overrepresented in BALs Relative to Controls, See Also Table S6
BALs without CF Pathogensa
No non-conventional taxa were significantly overrepresented in BALs without CF pathogens as compared to controlsb
BALs with CF Pathogensc
Taxa Overrepresented versus
Controlsb

Relative Abundance
in Controlsd (%)

Relative Abundance
in BALse (%)

FoldDifferencef

p Valueg

Streptococcus

0.88

4.90

3

1.9 3 10

4

Prevotella

0.40

2.23

2

1.6 3 10

5

Veillonella

0.07

0.48

3

5.9 3 10

7

Alcaligenaceae

0.00

1.72

19

9.9 x10

19

a

BALs considered ‘‘without CF pathogens’’ contained less than 150% maximum value in instrument and reagent controls (i.e., <164 CF pathogen
genome copies/mL).
b
Based on results of negative binomial test (see text).
c
BALs considered ‘‘with CF pathogens’’ contained more than 150% of the maximum value in instrument and reagent controls (i.e., >164 CF pathogen
genome copies/mL).
d
Mean relative abundance of OTU in all catheter pre-washes, scope pre-washes, and reagent controls studied.
e
Mean relative abundance of OTU in all BALs studied.
f
Fold difference calculated by dividing reads of indicated taxa in BALs by level in controls.
g
p values are for taxa abundance in BAL relative to controls.

Table S2), which indicated that CF pathogens outnumbered
Streptococcus, Prevotella, and Veillonella by 1,000- to 4,000fold in BALs of CF adults with mild to moderate lung disease
(Figure S6). Notably, these oral bacteria were far more abundant
in subject-paired sputum samples than in BALs (Figure S6).
Multivariate Analyses Implicate CF Pathogens in Lung
Inflammation
Although CF pathogens are generally acknowledged to cause
CF lung inflammation, the effect of oral organisms that may
inhabit lungs is less clear. Indeed, both beneficial (Filkins et al.,
2012; Zemanick et al., 2013) and detrimental (Conrad et al.,
2013) effects on inflammation have been postulated.
We first used pairwise linear regression models and found that
the BAL abundance of CF pathogens, Streptococcus, Veillonella, and Prevotella each correlated with neutrophil elastase, a
robust marker of disease-causing inflammation (Sagel et al.,
2007) (Figure 5D). However, Streptococcus, Veillonella, and
Prevotella and CF pathogen abundances were strongly correlated in these BALs (Figure 5B), so pairwise associations could
be spurious.
We, thus, used multivariate regression modeling, and again
found CF pathogen abundance significantly associated with
neutrophil elastase levels in all models tested (Figure 5E). Indeed,
for each log10 increase in CF pathogen abundance, neutrophil
elastase increased by nearly 0.4 log10 mg/mL. For reference, the
primary anti-inflammatory medicine used in CF (azithromycin)
was found to reduce neutrophil elastase by 0.2 log10 mg/mL (Saiman et al., 2003). In contrast, models incorporating Prevotella,
Streptococcus, or Veillonella abundance identified no positive
or negative effect of these organisms (Figure 5E). Prevotella,
Streptococcus, and Veillonella exhibited significant collinearity
and could not be analyzed in the same model.
Effect of Treatment on Results
We investigated the potential effects of antibiotic and anti-inflammatory medications on the data. We found no differences
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in BAL bacterial DNA abundance or neutrophil elastase in subjects that were (n = 16) or were not (n = 6) taking antibiotics
and were (n = 15) or were not (n = 7) taking anti-inflammatories
(Figures S7B–S7E). Principle coordinate analysis of MorisitaHorn dissimilarities showed that the BALs did not cluster based
on antibiotic use (Figure S7F). Indeed, the batch of reagents used
for processing appeared to have a more pronounced effect than
antibiotics (Figure S7G). Furthermore, the abundance of Streptococcus, Veillonella, and Prevotella was actually higher in BALs
from antibiotic-treated subjects (Figure S7H). These observations may be related to our finding that Streptococcus, Veillonella, and Prevotella were more abundant in BALs with more
CF pathogens and argue against antibiotic use as an explanation
for the low abundance of oral organisms detected in these BALs.
Sequencing Can Produce False Positive Results
The strong association between CF pathogens and inflammation
indicates that the accurate detection of pathogens is critical. We
compared CF pathogen identification by clinical laboratory cultures and sequencing, limiting analysis to BALs studied by
both methods. As shown in Figure 6A, in 11/14 cases, the CF
pathogen genera identified by the clinical laboratory were also
identified as highly abundant by 16S sequencing. In 2/18 BALs
(from subjects 7 and 8), the clinical lab identified multiple CF
pathogens, and in these cases, only 1 pathogen was detected
by sequencing. However, culture detection of CF pathogens
was generally corroborated by sequencing results.
In contrast, our data indicate that it could be challenging to use
sequencing data in isolation to determine if CF pathogens are
present or absent. On average, 13% of the sequences in scope
and catheter pre-washes mapped to CF pathogens (Figure S1C)
even though these control samples were obtained prior to any
contact with subjects. Furthermore, BALs from the 3 subjects
that were culture negative for pathogens (subjects 6, 9, and 15)
and whose BAL-1a had low levels of neutrophil elastase contained CF pathogen sequences at a relative abundance of 5%,
14%, and 16% (Figure 6B).

(legend on next page)
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Figure 6. Sequence-Based Bacterial Identification Generally Agrees with Culture but Can Produce False Positives
(A) Sequencing and culture results of 18 BALs (i.e., BAL-4 samples) that were studied by both approaches. Taxa relative abundance (from sequencing) are shown
at left, and dashed boxes indicate taxa detected by culture. Culture results are listed at right, and pathogens indicated in red were not detected by sequencing at
appreciable levels (<1% relative abundance). We investigated the Bordetella results (indicated by a cross [✝]) by subjecting the Bordetella reference sequence in
the Silva database to BLAST analysis in the NCBI 16S rRNA database, and found the Bordetella reference highly similar to Achromobacter sp. Thus, reads
mapping to Bordetella may have originated from Achromobacter, as indicated by culture results. M. abscessus (indicated by *) may not have been detected by
sequencing because procedures used may not have lysed mycobacterial cells.
(B) CF pathogens were detected in culture-negative BALs. Stacked bar graphs show relative abundance of CF pathogens (colored bars) and non-conventional
organisms (black bars) in 3 culture-negative BALs and their subject-paired instrument control samples. The percentage of bacterial DNA mapping to CF
pathogens is listed below each bar.

These findings are consistent with supplemental data from
Hogan et al., (2016) (Table S2 in Hogan et al., 2016) indicating
that washes from bronchoscopes inserted to the level of the
vocal cords, but not entering subjects’ lungs, contained an
average of 24% CF pathogens. Notably, the CF pathogen
genera present in the scope wash controls and culture-negative

BALs from our study and scope washes from Hogan et al., (2016)
included Pseudomonas, Burkholderia, Achromobacter, and
others that typically prompt clinical treatment. These data suggest that accurate sequence-based detection of CF pathogens
could be problematic without extensive measures to minimize
and account for background contamination.

Figure 5. CF Pathogens Vastly Outnumber Non-conventional CF Organisms in BALs and Are Associated with Lung Inflammation
(A) The absolute abundance of CF pathogens, Streptococcus, Prevotella, and Veillonella in all 102 BALs plotted as a function of total BAL bacterial abundance.
(B) The absolute abundance of Streptococcus, Prevotella, and Veillonella in all 102 BALs plotted as a function of CF pathogen abundance.
(C). Ratios of the abundance of CF pathogens to Streptococcus, Prevotella, and Veillonella in all 102 BALs. Mean and SD are indicated.
(D) Pairwise correlation analyses of neutrophil elastase levels with CF pathogens, Prevotella, Streptococcus, and Veillonella in 22 BALs. Pearson correlation
coefficients and p values are shown, and red designates significant correlation (see Figure S7A for correlations between neutrophil elastase and age, BMI, and
FEV1 and bacterial DNA abundance Shannon diversity). In (A)–(D), each point represents measurements from individual BALs.
(E) Four multivariate regression models show that the abundance of CF pathogens positively correlated with neutrophil elastase, whereas Prevotella, Streptococcus, and Veillonella exhibited no positive or negative correlation. Error bars indicate 95% confidence limits of parameter estimates. Red indicates factors that
significantly correlated with neutrophil elastase in each multivariate model (*p < 0.05, ***p < 0.0005). Red dashed line indicates no effect on neutrophil elastase,
and the red arrow shows the negative effect of azithromycin on neutrophil elastase levels identified in Saiman et al., (2003) for reference.
See also Figures S6 and S7.
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DISCUSSION
We studied BALs from children with CF to address the following
questions about CF infection pathogenesis.
Do Diverse Communities of Mostly Oral Organisms
Dominate CF Lungs before Pathogens?
The analyses comparing BALs to subject-paired mouth and
throat samples indicated that the bacterial DNA in BALs with
low (essentially background) levels of CF pathogens were generally very different from subjects’ mouth and throat samples (see
Figures 3, 4, and S5) but similar to subject-paired instrument
controls. A statistical test corroborated these findings, finding
no non-conventional taxa that were statistically more abundant
in low-pathogen BALs than in instrument controls. Thus,
these findings do not support the idea that diverse communities
of oral organisms colonize lungs before CF pathogens.
Do Diverse Communities of Non-conventional
Organisms Co-exist with Pathogens?
Neither the negative binomial test nor the analysis that computationally removed CF pathogen reads found evidence for high-diversity communities of non-conventional organisms in BALs in
which pathogens were abundant (Figure 4). However, this analysis did identify three non-conventional taxa (Streptococcus,
Prevotella, and Veillonella) that were over-represented in these
BALs relative to controls. Notably, these organisms were not
over-represented (relative to instrument controls) in BALs that
lacked pathogens (Table 1, Figures 3G, 4A, and 5B), and when
present, they were vastly outnumbered by pathogens
(Figure 5C). Furthermore, multiple regression analysis found
that whereas CF pathogen abundance exhibited a strong positive association with airway inflammation, neither positive nor
negative effects of the low-abundance Streptococcus, Prevotella, or Veillonella were apparent (Figure 5E).
How Do We Interpret Differences in Microbial Diversity
Indices?
Studies using DNA-based analyses suggest that microbial diversity measurements (which are calculated from relative abundance data) are a key disease parameter as strong inverse relationships between diversity and lung function and age have been
observed (Coburn et al., 2015; Cox et al., 2010; Fodor et al.,
2012; Klepac-Ceraj et al., 2010; Stokell et al., 2015; Zhao
et al., 2012). Indeed, our study produced analogous findings,
as we found strong inverse relationships between Shannon diversity and BAL bacterial abundance (Figure 2B) and neutrophil
elastase (Figure S7A).
However, interpreting BAL diversity differences in the context
of absolute bacterial abundance data and accounting for contaminants present in subject-paired scope pre-washes suggested that decreases in BAL diversity were due to an increased
absolute abundance of CF pathogens added to a relatively constant background of non-conventional organisms that were
highly similar to the organisms present in scope pre-wash controls (see Figures 2D–2F). In other words, decreases in BAL
diversity appeared to be due primarily to increases in CF pathogens reducing the signal from contaminants. Importantly, an

analogous mechanism could operate in sputum samples as increases in CF pathogen abundance could reduce the signal
from diverse bacterial communities in contaminating oropharyngeal secretions.
Implications for CF Infection Pathogenesis
Although our findings were consistent with two major predictions of the established pathogenesis model (i.e., identifiable
microbiota were not detected before pathogen infection and
pathogens likely drive inflammation), our data raise questions
about the established model’s postulate that only CF pathogens are present. The low abundance of Streptococcus,
Prevotella, and Veillonella DNA found in BALs that contained
CF pathogens raises the possibility that these organisms can
cause superinfection of pathogen-infected lungs. If this were
the case, they could contribute to disease independently
or by interactions with established pathogens. However,
previous work also suggests that patients with more cough
and more advanced disease may experience more aspiration
(Blondeau et al., 2008; Blondeau et al., 2010); thus, it is
possible that the low abundance of Streptococcus, Prevotella,
and Veillonella DNA in BALs could be a consequence of
increased aspiration of oral secretions. These findings, together
with the regression modeling data finding no association between Streptococcus, Prevotella, and Veillonella abundance
with pathogen-associated inflammation indicate that additional
work is needed to determine if and how these organisms might
affect disease.
Comparing Results with Other Studies
Comparing results from studies that use DNA-based analyses is
challenging because of differences in patient characteristics,
specimen collection and processing and sequencing approaches,
and methods used to control for contaminants. Although several
factors may explain differences between our results and previous
work analyzing CF airway microbiomes (Carmody et al., 2013; Coburn et al., 2015; Cox et al., 2010; Filkins et al., 2012; Frayman
et al., 2017; Hogan et al., 2016; Pittman et al., 2017; Renwick
et al., 2014; Whiteson et al., 2014; Zemanick et al., 2013; Zemanick
et al., 2015; Zhao et al., 2012), we speculate that one key factor
was the use of cuffed endotracheal tubes for bronchoscopy that
were inserted by laryngoscopy under general anesthesia. This
approach eliminated scope contact with the oropharynx and likely
reduced contamination with oropharyngeal secretions. The saliva
of CF children has been reported to contain an average of 1010
bacteria/mL (Zemanick et al., 2015). Thus, mixing as little as
1/100 of a milliliter of saliva into 10 mL of BAL fluid or sputum could
produce a signal reporting 106 oral bacteria per mL. The sampling approach used here likely reduced upper airway contamination and, thus, decreased detection of oral organisms. Other
studies have used different approaches to control for contaminants, including using multiple bronchoscopes and protected
brushes to sample the airways (Hogan et al., 2016), sequencing reagent control samples (Muhlebach et al., 2018), and sequencing
oropharyngeal control samples (Zemanick et al., 2015), and the
different methods could produce different results.
Previous work using BAL is somewhat more analogous to this
study, but comparisons are still hampered by methodological
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differences. For example, studies that reached different conclusions about the abundance of oral organisms in CF lungs either
studied infants or very young children (Frayman et al., 2017;
Muhlebach et al., 2018; Pittman et al., 2017), did not analyze
data in reference to paired instrument or oropharyngeal controls
(Hogan et al., 2016), and in some cases performed BAL through
laryngeal masks (Frayman et al., 2017; Pittman et al., 2017; Renwick et al., 2014) or trans-orally (Hogan et al., 2016) rather than
by endotracheal tubes. Finally, as indicated above, interpreting
differences in diversity indices between samples using absolute
and relative taxa abundance values can lead to different conclusions. We speculate that these factors account for some of the
different conclusions reached between this and other studies.

work is needed that uses stringent sampling, extensive controls,
absolute abundance measurements, and perhaps novel approaches (such as differential immunoglobulin coating to identify
bacterial origin). This work will be critical because future progress depends upon accurately determining which bacteria are
present in the lungs of people with CF and contribute to disease.
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d
d

Study Limitations
Our study had several limitations. First, we collected crosssectional samples and more complete information about early
infections requires longitudinal sampling. For example, it is
possible that oral organisms could be present periodically and
transiently affect disease manifestations. Second, subjects underwent bronchoscopy for varying clinical indications and were
on physician-directed (rather than protocol-directed) treatments, and this likely introduced variability to the findings. The
use of bronchoscopies for clinical indications and the lack of longitudinal samples are difficult to avoid given the risks of general
anesthesia, endotracheal intubation, and bronchoscopy in
children.
Third, the DNA-based methods we used do not distinguish organisms that are living and replicating in the lung from those that
are deposited in the airways and then rapidly killed. This is particularly important for interpreting the low abundance of Streptococcus, Prevotella, and Veillonella in BALs dominated by pathogens, as work in non-CF subjects suggests that oral bacteria
may be aspirated and rapidly cleared from lungs (Dickson et al.,
2017). It is also important to note that although the statistical analysis found no evidence for these or other oral organisms in BALs
without pathogens, it is possible that they are present at very low
abundances and could not be resolved from background contaminants. In addition, this analysis compared the values and variance of taxa present in all BAL and controls as groups, and some
BALs could be outliers in terms of taxa composition.
Fourth, it was impractical to directly measure the absolute
abundance of each taxon identified. Thus, we calculated absolute abundances from measurements of total bacterial genome
copies and taxa relative abundance. Our validation experiments
suggest this approach is reasonable. Finally, we sampled a
limited number of lung sites (usually 4), only used BAL, did not
study non-CF children, CF children less than 5 years old, or those
with advanced disease, and did not have a cohort undergoing
defined pulmonary exacerbations. Sampling more sites, protected specimen brushes, and studying different subjects could
produce different results.
Conclusions
Identifying the bacteria infecting the lungs of CF children is
extremely challenging because the lungs lie distal to the heavily
colonized oropharynx, lung bacterial biomass can be low, and
reagents contain significant contaminating DNA. Additional
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human subjects
Patients were enrolled at the Cincinnati Children’s Hospital Medical Center with IRB approval. Twenty-two subjects between the
ages of 2-21 years old (14 females and 8 males) were recruited for participation in this prospective study if they had a documented
diagnosis of CF and were undergoing clinically indicated bronchoscopies. Participation in the study was voluntary, and participants
and/or parents provided informed consent prior to enrollment. We did not examine associations between subjects’ gender and results as the study objectives were to investigate using stringent sampling methods, multiple types of control samples, taxa absolute
abundance data, and within-subject comparisons to interpret BAL microbiome and inflammatory marker data.
METHOD DETAILS
Study design and sample collection
Samples were collected in the following order to limit and control for possible contamination sources. (1) An oral saline rinse was
collected to sample the mouth. (2) Sterile saline was drawn through a sterile catheter and saved as the first instrument control sample
(called ‘‘catheter pre-wash’’). (3) Using the catheter, a post-pharyngeal aspirate was collected. (4) Before beginning bronchoscopy,
the second instrument control sample was collected by drawing sterile saline through the bronchoscope (called ‘‘scope pre-wash’’).
(5) Patients were intubated to reduce oropharyngeal contamination during the bronchoscopy.
BAL for clinical care is generally performed in only 1-2 lobes as per the ATS guidelines (Faro et al., 2015), and use either fixed volumes of 10 to 50 mL per aliquot or weight-based volumes, typically 1 ml/kg per aliquot. The right middle lobe and lingula are the lung
segments most frequently sampled because they provide maximal return. Here we sampled four sites to increase the lung regions
sampled. The bronchoscope was inserted into the airways without suctioning if possible, and 2 BAL samples were collected consecutively from two adjacent segmental bronchi of the right middle lobe (BAL-1a and BAL-1b). The second lavage (BAL-2) was then performed in a segmental bronchus of the right upper lobe. The bronchoscope was then repositioned to the left lower lobe (BAL-3) and in
the lung segment that appeared most diseased during bronchoscopy, or on prior imaging (BAL-4).
All samples were immediately preserved in RNAlater solution to enable isolation of DNA and RNA from each sample. For a subset of
samples, a portion of the untreated sample was immediately frozen for later comparison to the RNAlater treated samples. Taxonomic
analyses showed that preservation in RNAlater did not affect the microbes detected in the samples by sequencing. Following collection, the BAL-4 was sent to the Cincinnati Children’s Hospital Medical Center Clinical Laboratory for microbial culturing.
DNA isolation
BAL, mouth rinse, throat aspirate, and bronchoscope and catheter pre-wash samples were thawed on ice, and DNA was isolated
using RNAbee, as previously described (Jorth et al., 2014). For each sample, 100 mL sample was combined with 1 mL RNA-Bee
in a lysing matrix B bead beating tube (MP Biomedical) and bead beat 3 times for 60 s each, incubating on ice for 1 m in between
each bead beating. Lysed supernatants were mixed with 200 ml chloroform (Fisher) and shaken vigorously for 45 s. Samples were
centrifuged at 13,100 g for 30 m at 4 C to separate organic and aqueous phases. Organic phases from each sample were mixed
with 500 mL TE buffer pH 8.0 (Thermo Fisher Scientific), shaken vigorously for 30 s, and incubated for 10 m on a tube roller at
25 C. Samples were centrifuged at 13,100 g for 30 m at 4 C to separate organic and aqueous phases. The DNA-containing aqueous
phase was combined with 750 mL 100% ethanol, 25 mL 3 M sodium acetate pH 5.5, and 1 mL 5 mg/ml linear acrylamide (Thermo Fisher
Scientific) to precipitate DNA. Samples were mixed by gentle inversion and incubated for at least 1 h at 80 C. Samples were centrifuged at 16,100 g for 15 m at 4 C to pellet DNA. DNA pellets were resuspended in 750 mL 75% ethanol and centrifuged at 16,100 g for
5 m at 4 C to wash the DNA. A second 75% ethanol was performed, and ethanol was removed. DNA pellets were air-dried for 5 m at
25 C and DNA was dissolved in 22 mL TE buffer pH 8.0.
Bacterial quantification
Bacteria were quantified in triplicate with 16S qPCR using 16S-CCF-qPCR-F and 16S-926R-qPCR-R primers (Table S7) with SYBR
FAST qPCR Master Mix (Kapa Biosystems) using the manufacturer’s protocol with a CFX96 Touch Real-Time PCR Detection System
(Biorad). Genomic DNA from P. aeruginosa PAO1 was used to generate a standard curve for quantification of genome copies per ml
of sample. A negative control sample (no template) was included with every standard curve. For every experiment, a standard curve
was run alongside samples.
16S rRNA gene sequencing
Sequencing libraries were produced by PCR amplification of 16S rRNA gene V3-V5 variable regions in triplicate reactions using 5 mL
DNA per reaction with HiFi HotStart ReadyMix (Kapa Biosystems) using the manufacturer’s protocol on a CFX96 Touch Real-Time
PCR Detection System (Biorad). PCR was performed in triplicate for each library. Indexed primers 926BC01-926BC96 (Table S7)
were used to uniquely identify each library, and primers contained Illumina-compatible DNA sequences for MiSeq sequencing.
For each library the triplicate PCR reactions were pooled. Pooled library reactions were purified and normalized using SequalPrep
Normalization Plates (Applied Biosystems), according to the manufacturer’s instructions. Normalized indexed sequencing libraries
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were combined and quantified using qPCR with the Library Quantification Kit for Illumina sequencing platforms (Kapa Biosystems).
Library size was verified and by Tape Station analysis with a High Sensitivity D1000 ScreenTape (Agilent) and taken into account for
quantification. The 16S rRNA gene sequencing libraries were sequenced on an Illumina MiSeq using paired 300 bp sequencing with a
600 cycle v3 MiSeq Reagent Kit (Illumina) using custom primers MiSeq-926R, MiSeq-926R-Index, and MiSeq-CCF, which were
spiked into MiSeq reagent cartridge wells 12, 13, and 14, respectively (Table S7).
16S rRNA gene sequencing analyses
Qiime was used to assign sequencing reads to OTUs, calculate Shannon alpha diversity for each sample, and calculate beta diversity
using the Morisita-Horn method (Caporaso et al., 2010; Horn, 1966). For each sequencing library, the 300 bp read 1 sequencing reads
were processed for Qiime using custom scripts. Reads were assigned OTUs by Uclust searching against the Silva rRNA database
(Quast et al., 2013). For each sample, reads were rarefied ten times to equal depth, 10,000 reads per sample. Alpha diversity was
quantified by calculating Shannon diversity for rarefied samples. Morisita-Horn jackknifed beta diversity was calculated with a depth
of 10,000 reads per sample when all taxa were included.
Pathogen-free taxonomic profiles were generated by filtering out Staphylococcus, Pseudomonas, Haemophilus, Burkholderia,
Stenotrophomonas, Achromobacter, Burkholderia, Bordetella, Inquilinus, and Escherichia-Shigella from the OTU table. MorisitaHorn jackknifed beta diversity was calculated with a depth of 900 reads per sample when only non-conventional CF organisms
were analyzed. To identify potential BAL-specific non-conventional organisms we compared all BAL samples with greater than
465 genome copies/ml (since these BAL samples have more bacterial content than the instrument controls and would likely have
true non-conventional organisms present) to the control group, which consisted of all catheter pre-wash, bronchoscope prewash, and reagent control samples. As a proof-of-principle we also compared the oropharyngeal samples consisting of all oral
and throat samples to the same control samples. DESeq2 was used to compare non-conventional CF taxa in BAL versus control
samples, as well as oropharyngeal versus control samples (Love et al., 2014).
Quantification of OTU absolute abundances
OTUs were quantified in this study by multiplying the total bacterial abundance determined by 16S rRNA gene qPCR by the relative
abundances of each OTU determined by bacterial 16S rRNA gene sequencing. As proof of principle, the same analysis was performed using our previous 16S rRNA gene qPCR and sequencing data from CF sputum collected in Ireland (Hisert et al., 2017).
To assess the validity of this quantification method, Pearson correlation analysis was used to compare the extrapolated OTU quantities for Streptococcus, Prevotella, Pseudomonas, Staphylococcus, and Haemophilus to the quantities of these organisms determined by genera-specific qPCR analysis.
Neutrophil elastase activity assays
Neutrophil elastase activity assays were performed on the BAL1a samples from all 22 patients by spectrophotometric detection of
the hydrolysis of MeO-suc-Ala-Ala-Pro-Ala-p-nitroanilide (Sigma Chemical Co, St. Louis, MO). As controls, untreated BAL-1a samples were compared to RNAlater treated BAL-1a samples from subjects 18, 19, and 20, and negligible differences were observed.
QUANTIFICATION AND STATISTICAL ANALYSIS
Pearson and Spearman correlation analyses were performed using Prism GraphPad. Multivariate linear regression was used to
examine independent effects on BAL neutrophil elastase of CF pathogens, Streptococcus, Prevotella, and Veillonella adjusted for
subject age. Neutrophil elastase was non-normally distributed and required log transformation. We employed model diagnostics
as follows: assessment of Studentized residuals; assessment of leverage by plotting leverage versus residuals-square, Cook’s Distance (Cook’s D), DFIT (a measure of overall measure of influence) and DFBETA. Models were rerun without influential points and
outliers to assess changes in coefficients. Quantile-quantile (q-q) plots (qqplots) of residuals were made to assess distribution of residuals. No influential data points were identified that altered the coefficients. Additional plots were of residuals against predicted
values were done to assess for evidence of heteroscedasticity along with the White test. Coefficients are presented as the point estimate with 95% confidence intervals and p values. A p value of % 0.05 was considered significant by convention. Graphs and statistical analyses were prepared with Prism GraphPad, Qiime, Microsoft Excel, and SAS software (Caporaso et al., 2010; SAS, 2014).
DATA AND SOFTWARE AVAILABILITY
Sequencing read data are available in the NCBI Sequence Read Archive under Bioproject accession number PRJNA495633.
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